Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate‐risk acute myeloid leukemia

Abstract

These observations support that leukemic blast heterogeneity detected by MFC has additional prognostic significance in de novo AML; however, the score system needs to be prospectively validated in future clinical trials before implementation.